The Food and Drug Administration on Friday approved the drug Zarxio, a cancer drug produced by Novartis' Sandoz unit as a lower-cost biosimilar alternative to Amgen's Neupogen.
Hospitals are just beginning to hash out contingency plans as the waiting begins for the U.S. Supreme Court to decide whether to end insurance subsidies in most of the country.
See a list of selected high-spend hospital products and devices, ranked by percentage change. Source: ECRI Institute. Published March 2, 2015, p. 34.
St. Luke's Health System in Idaho won't be forced to give up its recently acquired physician group just yet, a federal appeals court decided Wednesday.
Health insurers are hopeful policymakers would craft a workaround to keep federal subsidies flowing to low- and moderate-income Americans if the U.S. Supreme Court rules against the federal government.
Dr. Harold Varmus is resigning from the National Cancer Institute, effective March 31, ending an almost five-year tenure as director of one of the most prominent cancer research organizations in the country.
Blue Cross and Blue Shield of Massachusetts lost $119 million from operations in 2014 with the costs of hepatitis C drugs and other specialty medications contributing to the higher-than-expected loss.
Washington insiders expect the CMS to propose new requirements this month that will include the government's approach to fostering data-sharing in the use of electronic health records.
The U.S. Food and Drug Administration on Wednesday advised health providers not to cancel surgical procedures involving the use of medical endoscopes.
Bill Leaver will retire as CEO of UnityPoint Health in January 2016. Kevin Vermeer, the system's chief strategy officer, will become the next top executive.